GRAY News and Press, Graybug Vision Inc. From 04/13/22

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Dire...

Graybug Vision (NASDAQ:GRAY) said it plans to use its current cash to advance its eye treatments, GB-102, GB-401 and GB-501, to clinical readouts in 2023. Shares of the company rose +3.1% in premarket trading. The company's GB-102 is in development to treat wet age-related macu...

Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022 Phase 1 trial in glaucoma expected to commence in first quarter of 2023 Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter of 2023 N...

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - ...

Graybug Vision press release (NASDAQ:GRAY): FY GAAP EPS of -$1.69 misses by $0.06. As of December 31, 2021, the company’s cash, cash equivalents, and short-term investments totaled $63.7 million, compared to $95.0 million as of December 31, 2020. For further details see: Graybug ...

BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today provided an update on recent corporate developments and reported financial...

The following slide deck was published by Graybug Vision, Inc. in conjunction with this event. For further details see: Graybug Vision (GRAY) Presents At Annual SVB Leerink Global Health Conference

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medica...

BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will e...

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive...